A phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM).

e20061Background: Malignant pleural mesothelioma (MPM) is a disease that is resistant to chemotherapy and there remains an unmet need for better therapeutic options. Nintedanib (BIBF 1120) is an or...